Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Lanifibranor & Non-alcoholic Steatohepatitis (NASH)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

NCT03008070 - NATIVE - Lanifibranor vs placebo & Non-alcoholic Steatohepatitis (NASH): The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase III trials
Francque et al. 2021a N Engl J Med 385:1547-1558

…

References (Sources)

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque et al. 2021a N Engl J Med 385:1547-1558

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!